{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:06:48Z","timestamp":1782832008522,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40123-026-01378-1","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:44:04Z","timestamp":1775821444000},"page":"1761-1772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema: 1-Year Results from the China RHINE Subpopulation"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03622593","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiaorong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatobi O.","family":"Idowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-0945","authenticated-orcid":false,"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1378_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.","journal-title":"Eye Vis (Lond)"},{"issue":"11","key":"1378_CR2","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, et\u00a0al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580\u201391.","journal-title":"Ophthalmology"},{"issue":"11","key":"1378_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00417-008-0884-6","volume":"246","author":"XW Xie","year":"2008","unstructured":"Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1519\u201326.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"24","key":"1378_CR4","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1001\/jama.2021.22208","volume":"326","author":"L Wang","year":"2021","unstructured":"Wang L, Peng W, Zhao Z, et\u00a0al. Prevalence and treatment of diabetes in China, 2013\u20132018. JAMA. 2021;326(24):2498\u2013506.","journal-title":"JAMA"},{"key":"1378_CR5","volume":"33","author":"J Liu","year":"2023","unstructured":"Liu J, Liu M, Chai Z, et\u00a0al. Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030. Lancet Regional Health. 2023;33:100700.","journal-title":"Lancet Regional Health"},{"issue":"4","key":"1378_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14746","volume":"39","author":"T Peto","year":"2022","unstructured":"Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, Chakravarthy U. Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real-world study. Diabet Med. 2022;39(4):e14746.","journal-title":"Diabet Med"},{"issue":"5","key":"1378_CR7","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.5.28","volume":"64","author":"D Sharma","year":"2023","unstructured":"Sharma D, Zachary I, Jia H. Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases. Invest Ophthalmol Vis Sci. 2023;64(5):28.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1378_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM, et\u00a0al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;172:72\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1378_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35(5):1305\u201316.","journal-title":"Eye (Lond)"},{"issue":"11","key":"1378_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, et\u00a0al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"1378_CR11","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910666","volume":"11","author":"JT Regula","year":"2019","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, et\u00a0al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2019;11(5):e10666.","journal-title":"EMBO Mol Med"},{"key":"1378_CR12","unstructured":"Genentech Inc. (Last updated January 2023) Vabysmo (faricimab-svoa) [prescribing information]. https:\/\/www.gene.com\/download\/pdf\/vabysmo_prescribing.pdf. Accessed February 15, 2024."},{"issue":"10326","key":"1378_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"issue":"3","key":"1378_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s10384-023-00979-8","volume":"67","author":"M Shimura","year":"2023","unstructured":"Shimura M, Kitano S, Ogata N, et\u00a0al. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. Jpn J Ophthalmol. 2023;67(3):264\u201379.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1378_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100111","volume":"2","author":"N Eter","year":"2022","unstructured":"Eter N, Singh RP, Abreu F, et\u00a0al. YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale. Ophthalmol Sci. 2022;2(1):100111.","journal-title":"Ophthalmol Sci"},{"issue":"6","key":"1378_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et\u00a0al. Faricimab treat-and-extend for diabetic macular edema: 2-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"key":"1378_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol Auckl. 2016;10:939\u201346.","journal-title":"Clin Ophthalmol Auckl"},{"issue":"3","key":"1378_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000508335","volume":"65","author":"Y Wang","year":"2020","unstructured":"Wang Y, Lin Z, Zhai G, et\u00a0al. Prevalence of and risk factors for diabetic retinopathy and diabetic macular edema in patients with early- and late-onset diabetes mellitus. Ophthalmic Res. 2020;65(3):293\u20139.","journal-title":"Ophthalmic Res"},{"issue":"6","key":"1378_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01387-3","volume":"21","author":"YK Lin","year":"2021","unstructured":"Lin YK, Gao B, Liu L, et\u00a0al. The prevalence of diabetic microvascular complications in China and the USA. Curr Diab Rep. 2021;21(6):16.","journal-title":"Curr Diab Rep"},{"issue":"9","key":"1378_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2013.168118","volume":"310","author":"Y Xu","year":"2013","unstructured":"Xu Y, Wang L, He J, et\u00a0al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948\u201359.","journal-title":"JAMA"},{"key":"1378_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, et\u00a0al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence. 2022;16:587\u2013604.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"1378_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01510-0","volume":"20","author":"K Lai","year":"2020","unstructured":"Lai K, Huang C, Li L, et\u00a0al. Anatomical and functional responses in eyes with diabetic macular edema treated with \u201c1 + PRN\u201d ranibizumab: one-year outcomes in population of mainland China. BMC Ophthalmol. 2020;20(1):229.","journal-title":"BMC Ophthalmol"},{"key":"1378_CR23","unstructured":"Regeneron Pharmaceuticals Inc. (2023) EYLEA (aflibercept) [prescribing information]. https:\/\/www.regeneron.com\/downloads\/eylea_fpi.pdf. Accessed February 15, 2024."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01378-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:07:48Z","timestamp":1778749668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01378-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01378-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xiaorong Li, Xiaoling Liu, Qin Jiang, Zhifeng Wu and Mei Han have no conflicts of interest to disclose. Qiuyu Chen, Ruyuan Liu and Wenxin Liu are Employees of Roche China. Oluwatobi O. Idowu and Jeffrey R. Willis are Employees of Genentech, Inc. and shareholders of Roche. Xiaodong Sun is a Consultant for Alcon, Allergan, Bayer Healthcare, Carl Zeiss Meditec Inc., Innovent Biologics Inc., Kanghong Biotech Inc., Novartis, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"RHINE was conducted in accordance with the International Council for Harmonization E6 Guideline for Good Clinical Practice, tenets of the Declaration of Helsinki, US Food and Drug Administration regulations, the European Union Clinical Trials Directive (2001\/20\/EC) and all applicable local, state, and federal laws. Study protocols were approved by applicable institutional review boards and ethics committees before trial commencement. Informed consent was obtained from all individual participants included in the study. Investigators from the China RHINE subpopulation trial sites are listed in the Supplementary Table\n                      \n                      . Faricimab is approved for the treatment of diabetic macular edema, neovascular age-related macular degeneration, and macular edema secondary to retinal vein occlusion in multiple countries worldwide and is not currently approved for use outside these indications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}